Thyroid eye disease is one of the rarest and most vision-threatening autoimmune disease conditions that roots the muscles and fatty tissues behind the eye to become reddened and enlarged, leading to bulging eyes. In addition to the bulging appearance, patients could experience double vision and light sensitivity. However, this disease can lead to blindness in the future.
Raymond Douglas, MD, PhD, director of the Orbital and Thyroid Eye Disease Program at Cedars-Sinai said that the study demonstrates a medical treatment with teprotumumab is operative at reversing the appearances of disease, which is also giving new hope to the patients.
The patients were given the drug once every week for three weeks over a 21-week period. The result showed that patients who were managed teprotumumab experienced actual response in two doses or six weeks of administration. Also, after 24 weeks, the study presented 83% of people on the drug had considerable reduction in eye bulge against 10% of those on a placebo. The overall response rate was 78% among those patients taking the drug compared to 7% of people taking a sample.
This new discovery contributed to the fast track drug agreement by the U.S. Food and Drug Administration, which will be marketed under the brand name Tepezza. This would be first drug approved for the condition.